Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) Gross Profit: 2009-2025

Historic Gross Profit for China Pharma Holdings (CPHI) over the last 17 years, with Sep 2025 value amounting to -$59,654.

  • China Pharma Holdings' Gross Profit rose 88.52% to -$59,654 in Q3 2025 from the same period last year, while for Sep 2025 it was -$443,314, marking a year-over-year increase of 76.72%. This contributed to the annual value of -$2.0 million for FY2024, which is 606.42% down from last year.
  • Latest data reveals that China Pharma Holdings reported Gross Profit of -$59,654 as of Q3 2025, which was up 31.44% from -$87,010 recorded in Q2 2025.
  • China Pharma Holdings' 5-year Gross Profit high stood at $301,936 for Q4 2021, and its period low was -$1.0 million during Q2 2024.
  • For the 3-year period, China Pharma Holdings' Gross Profit averaged around -$231,769, with its median value being -$146,661 (2023).
  • Its Gross Profit has fluctuated over the past 5 years, first tumbled by 728.01% in 2021, then soared by 204.99% in 2023.
  • Over the past 5 years, China Pharma Holdings' Gross Profit (Quarterly) stood at $301,936 in 2021, then slumped by 85.86% to $42,682 in 2022, then tumbled by 285.46% to -$79,158 in 2023, then tumbled by 102.87% to -$160,589 in 2024, then spiked by 88.52% to -$59,654 in 2025.
  • Its Gross Profit stands at -$59,654 for Q3 2025, versus -$87,010 for Q2 2025 and -$136,061 for Q1 2025.